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Background. TheMeningitisVaccineProject (MVP)was established to address epidemicmeningitis as apublichealth
problem in sub-Saharan Africa and, to that end, worked to develop a group Ameningococcal conjugate vaccine, PsA-TT.
Methods. Experiences in 4 clinical trial sites are described. Culturally sensitive collaborative strategies were
adopted to manage acceptable communication methods, peculiarities with the consent process, participant medical
issues, community care, and death.
Results. The clinical trials were completed successfully through community acceptance and active community
collaboration. The trials also strengthened the capacities in the participating communities, and actively worked to
resolve community problems.
Conclusions. The understanding and integration of sociocultural realities of communities were major assets in
the conduct and acceptance of these trials. MVP succeeded in these sites and provided a sound example for future
clinical studies in Africa.
Clinical Trials Registration. ISRTCN78147026 (PsA-TT 002); ISRCTN87739946 (PsA-TT 003);
ISRCTN82484612 (PsA-TT 004); PACTR ATMR2010030001913177 (PsA-TT 006); and PACTR201110000328305
(PsA-TT 007).
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The Meningitis Vaccine Project (MVP) was established
to offer a solution for meningitis as a public health pro-
blem in Africa. To meet this goal, the project developed a
group A meningococcal conjugate vaccine (PsA-TT,
MenAfriVac), which was tested for safety and efﬁcacy
in countries and populations that would beneﬁt from
such a vaccine. However, conducting clinical trials in re-
source-limited communities is challenging. Ensuring
that the PsA-TT vaccine was of the highest quality
was a key factor in obtaining the trust and cooperation
of the people for whom the vaccine was developed.
While international (largely Western) standards exist
to ensure data quality as well as protecting the rights
and safety of trial participants [1], studies have shown
that these principles can be applied in non-Western
environments but require ﬂexibility and culturally
informed adaptations [2]. During the clinical develop-
ment of the PsA-TT conjugate vaccine, the MVP con-
ducted 8 trials in sometimes remote communities in
sub-Saharan Africa and in India.
This article focuses on the clinical experiences in
the following African sites: (1) Medical Research Coun-
cil (MRC) Unit, The Gambia; (2) Navrongo Health
Research Centre, Ghana; (3) Centre pour le Développe-
ment des Vaccins (CVD), Mali; and (4) Institut de
Recherche pour le Développement, Senegal. We em-
phasize community considerations and experiences in
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the conduct of studies in African sites and highlight important
lessons learned from these sites. Speciﬁcally, we detail the com-
munication systems in these communities, the informed con-
sent process, issues of medical care in rural communities with
suboptimal healthcare systems, and capacity strengthening.
We also describe how the death of a trial participant was man-
aged. More technical results from these studies are described
in accompanying articles [3–6].
CHARACTERISTICS OF THE SITES
The trial sites in The Gambia, Ghana, and Senegal were largely
rural whereas the Mali site was located in Bamako, the capital.
The predominant religion in The Gambia, Senegal, and Mali
sites is Islam, accounting for 90%, 77.5%, and 95% of popula-
tions, respectively, whereas at the Ghana site Christianity is the
predominant faith. Literacy rates are low at all sites, with subsis-
tence farming, cattle rearing, and trading being the major sourc-
es of income. Despite recent improvements in health indices,
these areas suffer high under-5 mortality: 98, 61, and 45 per
1000 live births in Mali, Ghana, and The Gambia, respectively
[7–9]. Seasonal and nonseasonal infectious and parasitic diseas-
es constitute the major disease burden and are part of the back-
ground when conducting clinical trials in these countries.
Although these conditions made the work challenging, it was
also important to test the safety and efﬁcacy of the vaccine pre-
cisely where this background disease burden is the norm.
COMMUNICATION
A sound and robust communication system in rural communi-
ties, and between health institutions and governments, is a key
element for the success of a clinical trial. After receiving permis-
sion to begin the trial from the relevant government agencies and
ethics committees [10], meetings were held in the local languages
with the key leaders in the community including the village head,
the religious leaders and village development committees, youth
and women’s group leaders, and other opinion leaders.
Initiation Meetings
This initial meeting sought permission for the trial team to carry
out the trial in the community. In The Gambia it is customary to
take kola nuts to the village elders to bless the contact. Similar
events were organized in Mali after leaders had informed the
public, usually at Friday prayers or through a network of advisors.
With the support of these leaders, large community engagement
meetings were then held. In Ghana, these large meetings are
termed durbars. In Senegal, the badiénou Gokh (women’s groups
dedicated to raising awareness about medical and health issues)
play a major role during these meetings. These meetings serve to
create a sense of partnership and to provide the opportunity to
answer questions regarding the current or previous trials that
may be raised by the communities.
Local health teams, village reporters, and community liaison
ofﬁcers also play a signiﬁcant role in sensitizing the communi-
ties; hence, it is essential to inform them of potential studies and
to seek permission to use their facilities where appropriate.
Local journalists were also contacted at the start of each trial,
to ensure the transmission of correct information as well as to
cultivate these relationships in the event that further media cov-
erage was required or if something went wrong [11].
Participant Engagement
After community participation was assured, potential partici-
pants were then approached depending on the trial requirements.
In studies involving children, the consent of husbands or heads of
the compound was usually obtained. This is particularly impor-
tant in rural settings [10, 12]. Mothers and other relevant house-
hold members were also engaged and alerted about the trial.
Experience soon taught that failure to include male members
often led to participant withdrawal in the course of the trial.
RUMOR MANAGEMENT AND RECRUITMENT
Rumors, usually negative, are known to be potentially disruptive
in any clinical trial [13].To avoid having rumors disrupt activities,
ongoing dialogue with the participants and communities is key.
Having a community liaison ofﬁcer who can monitor rumors is
an asset [14]. It was important for the trial team to be aware of
rumors quickly so that the rumor could be addressed in a timely
manner. For example, in The Gambia, Senegal, andMali, a rumor
arose that blood taken during the clinical trials was being sold in
Europe. This rumor could have signiﬁcantly impacted the studies
negatively, but the rapid intervention of the ﬁeldworkers and com-
munity liaison ofﬁcers successfully dealt with the issue in most
settings. However, if initial responses were not successful, the
trial team arranged to meet with other community members
and opinion leaders, and/or community durbars/meetings were
convened to address the issue. In some instances, the team ar-
ranged visits to the laboratory so that key members of the commu-
nity could observe how blood samples were processed.
To better manage rumors, the Mali site established a commu-
nication and crisis management team. This team was composed
of members of the community (imams, notables, town criers),
the chief neighborhood medical ofﬁcer, women’s and youth
representatives, investigators (including the principal investiga-
tor [PI]), ﬁeldworkers, and the internal communication team
leader. This team held regular meetings to share information
about the trial and the trial population and sometimes met
heads of families to discuss speciﬁc concerns. In Senegal, 1 or
2 members of the trial team were designated to speciﬁcally man-
age rumors under the supervision of the PI. These persons were
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authorized to communicate on the project with the media and
to the community (Table 1).
The communities in Ghana and The Gambia have several de-
cades of experience with medical research, so there already exist-
ed a general understanding and trust with the site trial teams.
This was an advantage, but care needs to be maintained to ensure
that a rumor is not mishandled or trivialized. As a basic rule,
proper understanding of the political dynamics and the culture
of the trial communities, particularly in low-literacy areas, is es-
sential for the successful completion of these trials (Table 2).
SHARING RESULTS WITH THE COMMUNITY
Community feedbackmeetings at the end of the trials also proved
useful in informing participants that studies had ended and for
sharing study results. Although these results were presented in
broad terms, sharing the information helped the communities
to develop a sense of ownership and accomplishment, especially
after introduction of the PsA-TT vaccine. Some sites noted that
the level of participation in mass vaccination campaigns had
greatly increased, which may have been related to improved
awareness of the vaccine as a result of the clinical trial (Figure 1).
CONSENT AND SUBJECT PARTICIPATION
Informed consent is based on a clear appreciation and under-
standing of the facts and the consequences of participating in
a clinical trial. Obtaining informed consent was therefore
quite challenging in these illiterate populations. One such chal-
lenge consisted of developing information in the local languages
that matched the original English information sheets. Obtaining
back-translations was a necessary and challenging process. De-
tails of this process are highlighted in an accompanying article
that focuses on ethical issues [10, 12].
In these communities, male members often have the ﬁnal say
on the consent process even when they are not present. Thus in
some instances, the consent had to be done in stages to accom-
modate this cultural peculiarity. Also, it was rather challenging
to get parents to accompany older minors to the clinics for the
consent process. Thus, for many in this group it was sometimes
necessary to go to the participant’s home to sign the consent
form. In addition, regarding consent of minors, Good Clinical
Practice (GCP) allows for the consent of legal guardians [1]. In
these communities, children are often in the custody of more
people than just the parents, and in practice this meant that it
was not always easy to ascertain who was a legal guardian. The
child belongs to the family, so almost any adult could take care
of the child and hence decide on behalf of the child. Document-
ed legal guardianship is important however, as some studies
have documented that guardians are more willing to allow par-
ticipation in trials of children other than their own [14, 15].
With infant trials it was easier to identify a parent, but with
older children care had to be taken to establish who a legal
guardian was. In MRC Gambia, the rule is to accept parental
consent, except when there is written documentation of legal
guardianship. This remains culturally sensitive in communities
where such extended family arrangements are the norm, and re-
search teams may be viewed as usurping this valued tradition.
An impartial witness is required by GCP when obtaining
consent from illiterate participants [1]. A major difﬁculty in
The Gambia and Senegal was ﬁnding literate and impartial in-
dividuals in these rural areas where literacy rates are quite low.
In The Gambia, it was customary to use school teachers or
health workers who may then need to serve as witness for sev-
eral participants. Participants were, however, encouraged to
come with their own witnesses whenever possible.
REASONS FOR TRIAL PARTICIPATION
Trial participation was viewed by some as a sign that their child
was considered healthy. However, in Mali, many mothers also
expressed fear that their child may come down with meningitis,
the illness the vaccine was designed to prevent.
Refusals/withdrawals tended to stem from community or
family perceptions. For instance, a participant >18 years of
age withdrew from the trial: his father had been away at the
time the trial started, but was consulted on his return home.
As the father, he needed to assert his ﬁnal say in participation
Table 1. Common Questions/Statements Arising Due to Rumors
• Since you collected a blood sample from my child, he became ill.
• Since you vaccinated my child, he is no longer growing normally.
• You are going to sell our children’s blood in the United States/
Europe.
• You use our children as guinea pigs.
• You want to give an expired vaccine to my child.
• White people (Toubabs) want to sterilize our children to prevent
them from having children.
• If you receive the vaccine, you’ll die before you are 30 years old.
• Your vaccine did not receive publicity on television or radio.
• Why do you need my signature to have my child enrolled? Is my
word not good enough?
Table 2. Measures Used to Deal With Rumors
• Communication and crisis management teams
• Prompt identification of rumor source
• Repeated and ongoing engagement of community, village
reporters, local health staff, etc.
• Gaining understanding of political dynamics, perception of
disease, vaccination, and death of various communities
• Use of locally understandable illustrations to explain study
procedures, disease, and death
• Reassuring the population of the study follow-up by health
authorities after approval of the study to ensure their safety
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irrespective of the fact that the participant was above the legal
age for that country.
SENSITIVITY OF BLOOD DRAWS
In some settings, issues concerning blood and blood draws are
sensitive, and if not properly handled could jeopardize a trial.
Due to the low literacy rate, the (small) amount of blood that
is collected could be scary, especially in infants. In some places,
it is believed that taking the blood of children could make them
ill. Hence, blood sample collection played a major role in refusal
or withdrawal from the trial. In addition, questions asked before
consent mainly centered on the procedures to be carried out,
what would be done with biological samples that were collected,
and why so many forms needed to be understood and signed
before enrollment. MVP conducted a safety trial that recruited
about 6000 subjects in Bamako, Mali. There was no blood draw
in the trial, and the experience suggested that recruitment was
comparatively easy and the participants’ completion rate was
high compared with trials requiring several blood draws [16].
CARE FOR THE PARTICIPANT
In MVP studies, clinical care was offered to all participants in
line with the treatment policy of the countries. In sites with clin-
ical trials experience, it is perceived that the quality of care given
to trial participants is better. The availability of medical care
appears to be a major incentive for trial participation. Moreover,
former participants continued to visit the site to request care
even after the studies, further indicating that the availability
of quality of medical care is considered important. In practice,
trial clinicians also provided counsel and care to immediate
family members of the participants.
CARE FOR THE COMMUNITY
Communities further beneﬁted from improved medical care
when recruitment and other clinic activities were conducted
in communities rather than in the hospital. Normally, commu-
nity clinics are staffed by community health nurses, but during
the trial, trial doctors also provided medical care at these facil-
ities, and supervised the community health nurses, which likely
led to better patient care. This indirect beneﬁt to the community
is often used as an argument for clinical trial participation, es-
pecially in community meetings and durbars.
SPECIAL ADDITIONAL COMMUNITY
PROGRAMS
Mention should also be made of special programs instigated in
response to the needs in the community. In The Gambia and
Mali, clusters of children with malnutrition from a certain re-
gion were observed. Following a recommendation by the data
safety monitoring board (DSMB) that the team intervene, a
Figure 1. Research team providing information to community at recent feedback meeting in The Gambia. Photo credit: Abdoulie Cham, MRC Unit, The
Gambia.
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community mobilization effort was mounted in the worst-hit
communities to demonstrate how to provide healthy meals
for infants with locally available food. In addition, a monitoring
system was established that was based on World Health Orga-
nization standards. Regular deworming of children was also
done. These efforts were much appreciated by the community,
and communities took ownership by assisting in running such
demonstrations. Four years after the trial began and at the kick-
off meeting for the antibody persistence study, this community
intervention to improve nutrition was still a major topic of dis-
cussion at the community meetings, with key leaders applaud-
ing the research team’s efforts and impact.
In Navrongo, Ghana, it was noted during the course of the trial
that there was a high incidence of malaria in the infants recruited
in the trial, resulting in large number of serious adverse events.
After consultation with the DSMB, MVP undertook an insecti-
cide-treated bed-net distribution campaign in the trial area. This
distribution was targeted not just at trial participants, but at all
families in the community with children <3 years old. Data
collected from the local district health units suggested a reduction
in the number of conﬁrmed cases of malaria.
HANDLING PARTICIPANT DEATH
Formal autopsies could not be conducted at most sites, either due
to the religious requirement to bury the deceased within 24 hours
of death or the unavailability of autopsy facilities. Verbal autop-
sies were used to deﬁne the possible causes of death, especially
when the participant did not die in hospital. The trial teams in
each site expressed their sympathy and condolences. When nec-
essary, further support was offered, for example, in transporting
the deceased to the family. Such support further deepened the
trust in the investigative team by conveying a message of genuine
care and respect for the culture of the community.
IMPACT OF TRIALS ON CAPACITY
STRENGTHENING
MVP studies helped to strengthen the capacity in the sites where
they were conducted. In Basse Health Centre, The Gambia, at the
CVD clinic in Mali and at the Toucar health post in Senegal, fa-
cilities were upgraded. For all sites, new equipment was supplied,
such as resuscitation equipment and refrigerators that would
beneﬁt the facility beyond the duration of the trial.
Trial staff were regularly trained and new skills offered (eg,
enzyme-linked immunosorbent assay testing).
In Ghana, MVP contributed to the writing and revision of
guidelines for the treatment of common illnesses in the child-
ren’s ward of the district hospital. In The Gambia, the children’s
ward of the local health center was refurbished, and regular
training in management of common ailments was provided
for local health staff. The 4 MVP trial sites are also health facil-
ities for the surrounding communities, and the conduct of clin-
ical trials ensured an investment in the quality of these facilities.
CONCLUSIONS
The understanding and integration of sociocultural realities of a
community are major assets in the conduct and acceptance of
clinical trials. Most challenges observed were due to the cultural,
economic, and epidemiological setting, and the bottom-up ap-
proach to the interventions was very successful. Despite reli-
gious differences at sites and between sites, there were no
major differences in the challenges encountered between sites.
Attempts by the trial team to help reduce community problems
increased the trust communities had in investigators because it
highlighted important community issues beyond the trial. MVP
has made an important mark across all of its study sites and left
an example that, if emulated, could facilitate future studies.
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